The J.P. Morgan Healthcare Conference is a place for the well-heeled to get a readout on the next six-figure cancer drug, or learn about the gene-altering technology promising to defang a debilitating disease and send stock prices soaring.
But at this year s conference, investors also entertained pitches from a part of the industry known more for its enduring economic problems than its profit potential: the humble primary care practice.